The global nucleic acid isolation and purification market size was estimated at around USD $5.11 billion in 2022 and it is projected to hit around USD $13.33 billion by 2032, growing at a CAGR of 10.06% from 2023 to 2032.
Report Scope of The Nucleic Acid Isolation And Purification Market:
|Market Size In 2022||USD $5.11 Billion|
|Revenue Forecast By 2032||USD $13.33 Billion|
|Growth Rate From 2023 to 2032||10.06%|
|Segments Covered||Product, Type, Method, Application, End-Use|
|Market Analysis (Terms Used)||Revenue In USD Million/Billion And CAGR From 2023 To 2032|
|Regional Scope||North America; Europe; Asia Pacific; Latin America; MEA|
|Key Companies Profiled||QIAGEN; ThermoFisher Scientific Inc.; Illumina Inc; Danaher; F. Hoffmann La Roche Ltd; Merck KGGA; Agilent Technologies Inc.; Bio-Rad Laboratories; Takara Bio Inc; Promega Corporation; New England Biolabs; LGC limited; ABCAM PLC; Norgen Biotek Corp; Autogen Inc; Biogenuix, PCR Biosystems; Maggenome; Axon Scientific Sdn. Bhd; Macherey-Nagel GmbH & Co. KG|
The market expansion is fueled by several factors such as the rise in adoption of sequencing platforms in clinical diagnostics, growth in genomics & enzymology-based research, and increase in investments in R&D. In addition, the significance potential of molecular biology and advancement in precision medicine are further augmenting market growth. Increasing efforts of market participants to strengthen the capabilities of precision medicine for effective disease prognosis are facilitating market expansion. For instance, in September 2022, Avesthagen Limited launched the first fully integrated personalized genetic testing service AVEN Diagnostics. This service utilizes advanced technologies to advance the diagnosis process.
Privatization of the production of therapeutics with commercial potential, such as vaccines and peptide-based drugs, to suffice healthcare needs is driving the demand for large-scale separation instruments Thus, the nucleic acid isolation and purification industry exhibits lucrative growth potential. In addition, increasing automation in the industry, technological advancements, availability of benchtop instruments, and increasing investments from pharma companies has further supported the market. For instance, in April 2022 Zymo Research and Star Array announced a strategic investment to acquire Star Array, a biomedical company in Singapore. This strategy allowed Zymo to combine its nucleic acid purification technology with Star Array’s automation technique to expand its diagnostics portfolio.
Rapidly evolving biotechnological applications in various industries, such as food processing, agriculture, recycling & waste management, and energy & environmental, are projected to drive the adoption of nucleic acid isolation and purification. Also, factors such as growing pharmaceutical production, leveraged support for the biotechnology industry from the government, support in the regulatory framework, continuous R&D efforts, and ongoing research activities. These factors are expected to drive the market in the near future. For instance, in June 2022 Molzym received a fourth round of funding to strengthen its offering in microbial DNA isolation technology.
Moreover, increasing collaboration and expansion undertaken by leading market players to bolster their nucleic acid extraction modalities is another factor propelling industry growth. For instance, in April 2020 QIAGEN and Gilson collaborated to make manual nucleic acid extraction more efficient and reproducible. This collaboration integrated QIAGEN’s manual nucleic acid extraction kits and TRACKMAN Connected digital bench tool to enhance yield as well as efficiency.
Furthermore, Formalin-fixed, paraffin-embedded (FFPE) samples play a crucial role in determining the molecular correlates of carcinogenesis. However, the labor-intensive process of extracting nucleic acids from these samples and the potential for nucleic acid damage pose significant obstacles, limiting the use of FFPE samples. To address these challenges, companies are introducing novel isolation kits to facilitate the recovery of nucleic acids. For instance, in September 2022, Akadeum Life Sciences, Inc. announced the early access launch of a large-scale cell isolation kit for leukopaks. This research-use-only (RUO) kit aims to address workflow challenges in the laboratory.
Global Nucleic Acid Isolation And Purification Market Report Segmentation: